MUC1 and lung cancer: However, this study was not designed to collect data on baseline KL-6 levels at the time of diagnosis of patients with idiopathic ILD, and we did not focus on the validation of serum KL-6 levels as a predictive and prognostic biomarker of idiopathic ILD in patients without lung cancer.